50 related articles for article (PubMed ID: 16029222)
1. The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions.
Villemure S; Trenaman SC; Goralski KB
Expert Opin Drug Metab Toxicol; 2023; 19(6):329-332. PubMed ID: 37345482
[No Abstract] [Full Text] [Related]
2. Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2.
Choi YH; Lee U; Lee BK; Lee MG
Br J Pharmacol; 2010 Oct; 161(4):815-29. PubMed ID: 20860661
[TBL] [Abstract][Full Text] [Related]
3. Non-pharmacological treatment of depressive disorders: a review of evidence-based treatment options.
Dirmaier J; Steinmann M; Krattenmacher T; Watzke B; Barghaan D; Koch U; Schulz H
Rev Recent Clin Trials; 2012 May; 7(2):141-9. PubMed ID: 22353197
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.
Farid NA; Payne CD; Small DS; Winters KJ; Ernest CS; Brandt JT; Darstein C; Jakubowski JA; Salazar DE
Clin Pharmacol Ther; 2007 May; 81(5):735-41. PubMed ID: 17361128
[TBL] [Abstract][Full Text] [Related]
5. Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.
Khalilieh S; Yee KL; Sanchez RI; Triantafyllou I; Fan L; Maklad N; Jordan H; Martell M; Iwamoto M
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872071
[TBL] [Abstract][Full Text] [Related]
6. [Brown urine : Myoglobin-induced renal failure after concomitant administration of simvastatin and amiodarone].
Pietsch U; Müller-Höcker C; Filipovic M
Anaesthesist; 2016 May; 65(5):366-8. PubMed ID: 27142363
[TBL] [Abstract][Full Text] [Related]
7. Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.
Dingemanse J; Nicolas LB; van Bortel L
Eur J Clin Pharmacol; 2014 Jun; 70(6):675-84. PubMed ID: 24728182
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of midazolam in resuscitated patients treated with moderate hypothermia.
Bastiaans DE; Swart EL; van Akkeren JP; Derijks LJ
Int J Clin Pharm; 2013 Apr; 35(2):210-6. PubMed ID: 23192725
[TBL] [Abstract][Full Text] [Related]
9. Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits.
Sekhar MC; Reddy PJ
Mol Cell Biochem; 2012 May; 364(1-2):159-64. PubMed ID: 22227917
[TBL] [Abstract][Full Text] [Related]
10. [New aspects of perioperative statin therapy].
Butte N; Böttiger BW; Liakopoulos O; Teschendorf P
Anaesthesist; 2010 Jun; 59(6):539-48. PubMed ID: 20461348
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi DH; Chung JH; Choi JS
Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
[TBL] [Abstract][Full Text] [Related]
12. Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil.
Srinivas NR
Eur J Clin Pharmacol; 2008 Nov; 64(11):1135-6. PubMed ID: 18661126
[No Abstract] [Full Text] [Related]
13. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi DH; Shin WG; Choi JS
Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
[TBL] [Abstract][Full Text] [Related]
14. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.
Mc Donnell CG; Shorten G; Van Pelt FN
Anaesthesia; 2005 Aug; 60(8):747-53. PubMed ID: 16029222
[TBL] [Abstract][Full Text] [Related]
15. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes.
Toda T; Eliasson E; Ask B; Inotsume N; Rane A
Basic Clin Pharmacol Toxicol; 2009 Nov; 105(5):327-32. PubMed ID: 19663817
[TBL] [Abstract][Full Text] [Related]
16. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
17. Effect of HMGCoA reductase inhibitors on cytochrome P450 expression in endothelial cell line.
Bertrand-Thiebault C; Masson C; Siest G; Batt AM; Visvikis-Siest S
J Cardiovasc Pharmacol; 2007 May; 49(5):306-15. PubMed ID: 17513950
[TBL] [Abstract][Full Text] [Related]
18. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
